acelityBrunswick Group is advising Acelity Holdings on the PR front as the San Antonio-based medical technology developer focused on wound care and regenerative medicine eyes an initial public offering that could raise as much as $1B.

Acelity reported 2014 revenue of nearly $1.9B, the bulk of it (76%) from its Advanced Wound Therapeutics and Regenerative Medicine units.

The filing listed $100M as a placeholder value of the IPO, but Renaissance Capital reported that the offering could fetch as much as $1B.

Brunswick New York partner Jayne Rosefield and Dallas-based directory Lauren Nadig handle Acelity. Cheston Turbyfill, a Weber Shandwick alumn, is VP of corporate communications for the company.